"Novartis is conducting a thorough review of the situation and currently expects to resolve the issues and resume some supply in the next six weeks", the Swiss company said.
The drugmaker added in a statement that some doses of cancer therapy Lutathera would be available in Europe and Asia from a site in Spain, but there might be some delays in supply.
Lutathera and Pluvicto are both so-called radioligand therapies. The U.S. FDA approved Pluvicto in March for treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).
Lutathera was approved in 2018 to treat somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
By Reuters Staff
Posted on
Previous Article
« Proton-beam therapy increasingly popular in the U.S. Next Article
Intra-articular steroid/lidocaine injection improves hip arthritis pain, function »
« Proton-beam therapy increasingly popular in the U.S. Next Article
Intra-articular steroid/lidocaine injection improves hip arthritis pain, function »
Related Articles
December 31, 2021
Second-generation antiandrogens linked to higher depression risk
August 21, 2020
PSMA PET-CT staging is 27% more accurate
March 24, 2021
Signature DNA alterations in subtypes of bladder cancer
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy